Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341510 | 0.82 | CYP2C19 (0.62) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL22456073 | 0.82 | MAPT (0.67) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL8564086 | 0.82 | MAPT (0.61) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL16044320 | 0.82 | MAPT (0.61) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL4240648 | 0.80 | PKM (0.49) | MAPTPOLBPKMLMNAMAPK1 | |
| SCHEMBL22455941 | 0.80 | MAPT (0.61) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL737318 | 0.79 | MEN1 (0.62) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL28586443 | 0.79 | POLB (0.54) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL8883294 | 0.78 | MAPT (0.59) | MAPTTDP1POLBPKMLMNA | |
| SCHEMBL7371227 | 0.76 | RAB9A (0.61) | MAPTTDP1PKMLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1718642-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082901-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | MAPT 1769/4885TDP1 729/4885POLB 3279/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | MAPT 2228/4885TDP1 549/4885POLB 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.